Figure 3From: Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials Meta-analysis of three randomized trials compared indacaterol 300 μg once daily with placebo. Relative to placebo, patients receiving indacaterol 300 μg once daily are more likely to achieve TDI score equal to or greater than one unit.Back to article page